3rd Quarter - Report

LUNDBECK LLC for LUNDBECK LLC

Firm
Client
Income
—
Expenses
$225,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Monitor pricing investigation

LobbyistCovered position, as disclosed
MICHAEL J EGING —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

S. 525, HR 1298 - Drug Reimportation and impact in inlicensed and out-licensed products, impact on smaller pharmaceutical companies HR 1427, HR 1548, S. 726 - Biosimilar prescription drugs, data exclusivity

Foreign entity interest: H. Lundbeck, identified on LD-1, researches, develops and commercializes medicines that could be imported under an importation program, and global safety of drug supply is a critical issue.

LobbyistCovered position, as disclosed
MICHAEL J EGING —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 525 (111th), H.R. 1427 (111th), H.R. 1548 (111th), S. 726 (111th), H.R. 1298 (111th)

Health Issues HCR

Health care reform, HR 3200, Access to and coverage of Specialty Pharmaceuticals, Removal of patient life-time caps, and specialty tiering of copayments Senate Finance Committee Health Reform Chairman's Mark S. 301 - Physicians payments transparency, preemption of State law

Foreign entity interest: H. Lundbeck, identified on LD-1, researches, develops and commercializes medicines that are utilized by patients in the United States and will be affected by health care reform.

LobbyistCovered position, as disclosed
MICHAEL J EGING —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 301 (111th), H.R. 3200 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.